Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens
- 1 April 1993
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 67 (4), 801-805
- https://doi.org/10.1038/bjc.1993.146
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Can meta-analyses be trusted?The Lancet, 1991
- How American oncologists treat breast cancer: an assessment of the influence of clinical trials.Journal of Clinical Oncology, 1991
- The size of clinical trials in cancer research – what are the current needs?British Journal of Cancer, 1989
- A comparison of statistical methods for combining event rates from clinical trialsStatistics in Medicine, 1989
- Does chemotherapy improve survival in advanced breast cancer? A statistical overviewBritish Journal of Cancer, 1988
- Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.Journal of Clinical Oncology, 1985
- A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B studyAmerican Journal of Clinical Oncology, 1984
- A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancerBreast Cancer Research and Treatment, 1983
- A randomized comparative trial of adriamycin versus methotrexate in combination drug therapyCancer, 1978
- Statistical Aspects of the Analysis of Data From Retrospective Studies of DiseaseJNCI Journal of the National Cancer Institute, 1959